Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 2
Submit an article Journal homepage
3,767
Views
6
CrossRef citations to date
0
Altmetric
Articles

Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study

Peter Feng Wanga GSK, Upper Providence, PA, USACorrespondence[email protected]
View further author information
,
Christopher W. Yeeb Analysis Group, Inc., Boston, MA, USAView further author information
,
Boris Gorsha GSK, Upper Providence, PA, USAView further author information
,
Miriam L. Zichlinb Analysis Group, Inc., Boston, MA, USAView further author information
,
Prani Pakaa GSK, Upper Providence, PA, USAView further author information
,
Rachel H. Bhakb Analysis Group, Inc., Boston, MA, USAView further author information
,
Natalie Boytsova GSK, Upper Providence, PA, USAView further author information
,
Anamika Khanalb Analysis Group, Inc., Boston, MA, USAView further author information
,
Ahmed Nomanb Analysis Group, Inc., Boston, MA, USAView further author information
,
Maral DerSarkissianb Analysis Group, Inc., Boston, MA, USAView further author information
,
Shannon Ferrantea GSK, Upper Providence, PA, USAView further author information
&
Mei Sheng Duhb Analysis Group, Inc., Boston, MA, USAView further author information
 show all
Pages 398-406 | Received 13 Jun 2022, Accepted 15 Oct 2022, Published online: 21 Nov 2022

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Oriol, Philippe Moreau, Ian McFadden, Qing Xia, Mukta Arora & Meletios Athanasios Dimopoulos. (2024) An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leukemia & Lymphoma 0:0, pages 1-10.
Read now
Luciano J Costa, Thomas W LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador & Marco daCosta DiBonaventura. Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future Oncology 0:0.
Read now

Articles from other publishers (4)

Danai Dima, Aliya Rashid, James A. Davis, Leyla Shune, Al‐Ola Abdallah, Hong Li, Shaun DeJarnette, Jack Khouri, Louis Williams, Hamza Hashmi, Shahzad Raza, Joseph McGuirk, Faiz Anwer & Nausheen Ahmed. (2024) Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa ‐1 trial eligibility criteria: A real‐world multicentre study . British Journal of Haematology 204:4, pages 1293-1299.
Crossref
A. Visram, A. De La Torre, D. White, J. Su, E. Masih-Khan, M. Chu, V. Jimenez-Zepeda, A. McCurdy, R. LeBlanc, K. Song, H. Mian, M. Louzada, M. Sebag, D. Bergstrom, J. Stakiw, A. Reiman, R. Kotb, M. Aslam, C. Venner, R. Kaedbey, E. Gul & D. Reece. (2023) Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database. Blood Cancer Journal 13:1.
Crossref
Richard LeBlanc, Hira Mian, Donna Reece, Jiandong Su, Esther Masih‐Khan, Michael Chu, Victor Jimenez‐Zepeda, Michael Sebag, Kevin Song, Martha Louzada, Rami Kotb, Alissa Visram, Darrell White, Julie Stakiw, Antony Reiman, Muhammad Aslam, Debra Bergstrom, Rayan Kaedbey, Engin Gul & Christopher Venner. (2023) Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis. European Journal of Haematology 111:5, pages 815-823.
Crossref
Joseph YangNatalie BoytsovJosh J. CarlsonDouglas Barthold. (2023) Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis. Journal of Managed Care & Specialty Pharmacy 29:8, pages 917-926.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.